Wall Street Journal @WSJ reporter covering pharmaceutical industry. Contact me at 215-881-7127, peter.loftus@wsj.com.

Pfizer, Merck and Bristol-Myers Squibb Report Solid Results

wsj.com — Three major U.S. drug companies reported solid first-quarter results despite a strong dollar, amid signs that their increasing investment in new cancer drugs will be a key driver of Big Pharma's future growth. Pfizer Inc., Merck & Co. and Bristol-Myers Squibb Co.

AbbVie Earnings: What to Watch

blogs.wsj.com — Drug maker AbbVie (ABBV) is scheduled to report its first-quarter 2015 financial results on Thursday before the market opens. Here is what you need to know. EARNINGS FORECAST: Analysts surveyed by Thomson Reuters expect earnings of 85 cents a share, excluding certain items, up from 71 cents a share a year earlier.

Merck’s Keytruda Shows Improved Survival Odds for Melanoma Patients

wsj.com — Merck & Co.'s new cancer drug Keytruda improved the survival odds of patients with the skin cancer melanoma compared with Bristol-Myers Squibb Co.'s Yervoy, in the first head-to-head study of a new wave of drugs that harness the body's immune system to destroy tumors.

What to watch for in Johnson & Johnson earnings

marketwatch.com — By Peter Loftus Health-care giant Johnson & Johnson is scheduled to report its first-quarter 2015 financial results on Tuesday before the market opens. Here is what you need to know. Earnings: Analysts surveyed by Thomson Reuters expect earnings of $1.54 a share, excluding certain items, flat with a year earlier.

What to expect from Johnson & Johnson earnings

marketwatch.com — Health-care giant Johnson & Johnson is scheduled to report its first-quarter 2015 financial results on Tuesday before the market opens. Here is what you need to know: Earnings: Analysts surveyed by Thomson Reuters expect earnings of $1.54 a share, excluding certain items, flat with a year earlier.

How the Hottest Biotech Sprouted in Iowa

wsj.com — AMES, Iowa-This state leads the nation in hogs and corn, not biotechnology drugs. But one small firm here is drawing notice for its cutting-edge research on Ebola and cancer, despite being far removed from the drug industry's usual hubs. NewLink Genetics Corp.

Pharmalot…Pharmalittle…Good Morning: We’re Catching up on Eisai, HepC Research, Pfizer and Ebola

blogs.wsj.com — Good morning, readers. It's Friday, which means a weekend break upon us, but first there's some news to catch up on, so please scroll away. Cardiac biomarker provider Health Diagnostic Laboratory agreed to pay at least $47 million to settle civil allegations filed by the U.S.

Where Are The ‘Five Stars’ Merck Got From Schering-Plough?

blogs.wsj.com — The latest stumble in 's long-running attempt to bring the surgical drug Bridion to the U.S market is a harsh reminder of how unpredictable drug development-and industry mergers-can be. The U.S.

Judge Denies Amgen’s Request to Block Novartis’s Biosimilar of Neupogen

wsj.com — A federal judge denied Amgen Inc.'s request to block Novartis AG from selling a copy of an Amgen drug for chemotherapy patients in the U.S. U.S. District Judge Richard Seeborg in San Francisco issued an order Thursday finding that Novartis's Sandoz division was "within its rights" not to disclose certain information to Amgen about Novartis's proposed copy of the biotechnology drug, Neupogen, according to a court document.

Lilly joins with Chinese biotech to develop, market cancer drugs

marketwatch.com — Eli Lilly & Co. agreed to form one of the broadest collaborations to date between a large Western drug maker and a Chinese biotechnology company, a sign of the pharmaceutical industry's interest in the Chinese market despite recent growing pains.
More Articles →
May 02, 2015

RT @dinahwbrin: Frank Olivo, 66, substitute Santa hit with snowballs at Eagles game po.st/MDjTHp via @phillydotcom

May 01, 2015

RT @robzirk: .@Loftus @WSJ Chart doesn't reflect actual Part D spending on those meds. Nexium rebates alone may exceed 60% forbes.com/sites/matthewh…

May 01, 2015

@RxRegA @WSJ I don't believe Nexium was generic in 2013. But could other generics have met the need for some of these brands?

May 01, 2015

Re Nexium atop Part D spend, this from 2002: Prilosec's Maker Switches Users To Nexium, Thwarting Generics on.wsj.com/12lKOT6 via @WSJ

Apr 30, 2015

A treatable disease? Kythera Wins FDA Approval for Double-Chin Treatment on.wsj.com/1Gxjv5f via @WSJ $KYTH

Apr 29, 2015

RT @stefaniei: Costly cancer drugs buoy earnings of Big Pharma. R&D paying off, but prices draw critics. on.wsj.com/1GtUI1X @loftus @jo…

Apr 29, 2015

RT @ArmstrongDrew: "Great quarter, guys." Why analysts congratulated companies more than 1,200 times bloom.bg/1PXyD2A pic.twitter.com/swsomUektz



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Email

For instructions on how to pitch Peter Loftus, email loftus@muckrack.com.


Share This Profile